Stephens analyst Jeff Garro initiated coverage of Certara with an Overweight rating and $28 price target. The company has created a positive feedback loop between gaining regulatory acceptance of biosimulation products use cases, landing new customers, and achieving regulatory success for those customers, the analyst tells investors in a research note. While the stock trades at a premium multiple, it is warranted, and shares have room to go higher if the company can outperform what look like "conservative" FY23 targets, Stephens added.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CERT:
- Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
- Certara downgraded to Equal Weight from Overweight at Barclays
- Certara price target raised to $27 from $22 at Credit Suisse
- Exponent Set to Join S&P MidCap 400; CVR Energy and Certara to Join S&P SmallCap 600
- Certara adds deep learning capabilities to D360
